AYUR-VEDA BIO-DEVELOPMENT LIMITED COMPANY
Update：2025/12/24
Industries
Main Industry
Biotechnology
Main Product/Service
OBI Pharma’s product and technology portfolio focuses on antibody-drug conjugates (ADCs) and enabling platforms. Core proprietary technologies include GlycOBI® glycan-conjugation platform, EndoSymeOBI®, ThiOBI®, HYPrOBI™, which enable plug-and-play compat
Founded Year
2018
Unified Business No.
50775252
Status
Active
Number of Employees
0
Total Paid-in
Capital
0 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.
Exclusive content for members
Members-only content. Please log in to access.
Introduction
OBI Pharma, Inc., founded in 2002 with its headquarters and R&D center in Taiwan, and subsidiaries in the United States and Australia, is a global clinical-stage oncology company. The company focuses on innovative cancer therapies, aiming to develop first
